Needham Rates MapLight Therapeutics (MPLT) buy, $42 Price Target
Needham maintains its buy rating with a $42 price target for MapLight Therapeutics, a 39.77% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Needham rated MapLight Therapeutics, Inc. ($MPLT) "buy" with a $42 price target on June 22, 2026.
Since the rating, $MPLT is up 15.1% after 1 week, up 18.5% after 1 month and down 74.2% to date (from the $29.79 close on Jun 22, 2026).
MPLT
MapLight Therapeutics, Inc.
Key Points
- Needham reiterated its buy rating on MapLight Therapeutics (MPLT) with a $42 price target on June 22, 2026.
- Needham's $42 price target implies 39.77% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $30.05 share price.
- Shares of MPLT traded near $30.47 on Tuesday, with a 52-week range of $12.24 to $33.28 and a market cap of about $1.35 billion.
- Analysts from firms like Stifel and UBS also have buy ratings, with price targets ranging from $36 to $48.
Get $MPLT trade alerts by text
We text you when insiders, Congress or big funds trade $MPLT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MapLight Therapeutics, Inc. alert may contain errors. Disclosures
On June 22, 2026, Needham reiterated its buy rating for MapLight Therapeutics, Inc. (NasdaqGS: MPLT), setting a price target of $42. Analyst Ami Fadia maintained this optimistic outlook as the stock traded around $30.47 on Tuesday.
Needham vs. the S&P 500
Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.
MapLight Therapeutics, Inc. Stock Up 274.7%
Shares of MapLight Therapeutics were trading near $30.47 on Tuesday. The company, with a market capitalization of approximately $1.35 billion, operates in the biotechnology sector, focusing on treatments for central nervous system disorders. The stock's 52-week range spans from $12.24 to $33.28, with a 50-day moving average of $28.92 and a 200-day moving average of $21.11. MapLight has a high current ratio of 22.91 and a quick ratio of 21.71, reflecting strong liquidity.
$MPLT price target
MapLight Therapeutics, Inc. daily closes and this analyst's $42 target. Not advice.
Analysts Set New Price Targets
On June 22, 2026, Needham maintained its buy rating and set a $42 price target for MapLight Therapeutics. Earlier in the month, Stifel also maintained a buy rating with a $36 target on June 2. UBS initiated coverage with a buy rating and a $48 target on May 27, while Craig-Hallum also initiated with a buy rating and a $43 target on May 21. Overall, the consensus among analysts is a buy rating, with a mean price target of $38.7 based on 10 analyst opinions.
About MapLight Therapeutics
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California. Led by CEO Dr. Christopher A. Kroeger, the company employs 133 people and focuses on developing therapies for debilitating central nervous system disorders. Its pipeline includes treatments for schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, Parkinson's disease, and other neuropsychiatric conditions.
Bottom Line
Needham's reiterated buy rating and $42 price target for MapLight Therapeutics highlight ongoing confidence in the company's potential. Investors are closely watching its progress in the biotechnology sector. As with all 13F filings and analyst ratings, these insights reflect past data and sentiment, and may not indicate current or future performance.
Related Filing Alerts
Source: Needham's rating change on $MPLT (Jun 22, 2026). Written by software, not financial advice. How we make alerts